RecruitingNCT06308354
Colorectal Cancer Dataset in Xijing Hospital From 2011
Sponsor
Xijing Hospital
Enrollment
40,000 participants
Start Date
Jan 1, 2011
Study Type
OBSERVATIONAL
Conditions
Summary
To compare the differences of clinical pathological, treatment and prognosis in the guided subgroups in colorectal cancer, the investigator enrolled all the colorectal cancer patients who underwent surgery and were hospitalized in the Xijing hospital.
Eligibility
Min Age: 18 YearsMax Age: 100 Years
Inclusion Criteria3
- \. Pathologically confirmed colorectal adenocarcinoma, including hereditary colorectal cancer syndrome, such as Lynch syndrome and familial adenocarcinoma tumor polyposis, Peutz Jeghers syndrome, juvenile polyposis syndrome, and serrated polyposis syndrome;
- \. Visit our center with complete medical records and pathological information;
- \. Colorectal cancer patients diagnosed between 2013 and 2023.
Exclusion Criteria4
- \. The patient has other colorectal malignancies other than adenocarcinoma;
- \. Malignant tumors adjacent to organs invading the colon and rectum;
- \. Malignant tumors from distant organs metastasize to the colon and rectum;
- \. Benign colorectal lesions; 5. Patients with recurrent colorectal cancer.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06308354
Related Trials
ALND vs ART in Positive Sentinel Node After Neoadjuvant Therapy in Breast Cancer
NCT0488992459 locations
Study on the Impact of Electroacupuncture Combined With Self-Acupressure on the Quality of Life of Patients With Early-Stage Breast Cancer Undergoing Chemotherapy
NCT066016211 location
Clinical Study of Acupoint Application on Relieving qi Deficiency and Constipation in Patients Undergoing Chemotherapy
NCT072769321 location
Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient
NCT071982171 location
Oral Chemotherapy, Targeted Therapy and Immunotherapy With/Without Radiotherapy as 3rd- or Later-line Therapy for Advanced MSS/pMMR Colorectal Cancer
NCT067646801 location